Takeda Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations

Simply Wall St

November 02, 2024

Takeda Pharmaceutical (TSE:4502) Second Quarter 2025 Results

Key Financial Results

Revenue: JP¥1.18t (up 13% from 2Q 2024).
Net income: JP¥92.0b (up from JP¥48.0b loss in 2Q 2024).
Profit margin: 7.8% (up from net loss in 2Q 2024).
EPS: JP¥58.15 (up from JP¥30.70 loss in 2Q 2024).

earnings-and-revenue-growth — TSE:4502 Earnings and Revenue Growth November 2nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Takeda Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 93%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 4.7% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are up 4.0% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for Takeda Pharmaceutical (of which 1 makes us a bit uncomfortable!) you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Takeda Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.